CTXR250117P1000
- 0.89
- 0.000.00%
Citius Pharmaceuticals Newsroom
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15%
Citius Pharmaceuticals Falls as It Looks to Raise $3M in Direct Offering
Express News | Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Sector Update: Health Care
Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Citius Pharmaceuticals Price Target Maintained With a $9.00/Share by D. Boral Capital
Express News | Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Sector Update: Health Care Stocks Decline Late Afternoon
Citius Oncology Retains Jeffries to Consider Strategic Alternatives
Citius Oncology To Explore Strategic Alternatives, Engages Jefferies As Exclusive Financial Advisor
Express News | Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
D. Boral Capital Upgrades Citius Pharmaceuticals(CTXR.US) to Buy Rating, Announces Target Price $9
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
D. Boral Capital Upgrades Citius Pharma to Buy, Announces $9 Price Target
Citius Pharma Analyst Ratings
Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
10-K: FY2024 Annual Report